Your session is about to expire
← Back to Search
Procedure
Axillary lymphadenetomy alone for Lymphedema
N/A
Waitlist Available
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 yr
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a low-risk surgical method to repair the lymphatic system during breast cancer-related surgery. It aims to prevent lymphedema, a condition where fluid buildup causes swelling. The study focuses on patients who have had breast cancer therapy and are at risk of developing lymphedema. The goal is to see if this procedure can reduce swelling and improve patients' quality of life. The surgery has shown potential to decrease lymphedema in breast cancer patients.
Eligible Conditions
- Lymphedema
- Truncal Lymphedema
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 yr
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 yr
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Bioiimpedance spectroscopy
Limb Volume
Lymphatic flow pattern of whole limb
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Group AExperimental Treatment1 Intervention
Group A will under axillary lymphadenectomy alone
Group II: Group BActive Control1 Intervention
Group B will undergo axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) using reverse mapping using the SPY System.
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,471 Previous Clinical Trials
17,501,698 Total Patients Enrolled
13 Trials studying Lymphedema
6,492 Patients Enrolled for Lymphedema
Share this study with friends
Copy Link
Messenger